Introduction {#Sec1}
============

73--90% of neuromyelitis optica spectrum disorder (NMOSD) patients diagnosed according to the 2015 International panel on NMO diagnosis have aquaporin-4 antibodies (AQP4-IgG) \[[@CR1], [@CR2]\]. It is presumed that at least a proportion of the remaining 10--27% of patients, classified as seronegative NMOSD have another disease specific antibody. Antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) have been increasingly reported in a variety of CNS neuroinflammatory conditions including patients with phenotypes typical for NMOSD \[[@CR3]\]. We aimed to determine the prevalence of MOG-IgG in AQP4-IgG-negative NMOSD.

Methods {#Sec2}
=======

The Walton Centre Neurosciences NHS Trust in Liverpool, United Kingdom, is a tertiary neurology hospital that hosts one of the two national multidisciplinary specialist clinics for patients with NMOSD and non-MS demyelinating disorders as part of the UK NMOSD service. We systematically reviewed all patients seen in this clinic over the last 4 years (after the availability of MOG-IgG testing), including clinical information, MRI, and antibody tests. Both AQP4-IgG and MOG-IgG were tested using a validated live cell-based assay with high specificity (John Radcliffe Hospital, Oxford, UK) \[[@CR4], [@CR5]\]. This study was approved by Research Ethics Service, NRES Committee London---Hampstead, Ref. no. 15/LO/1433.

Results {#Sec3}
=======

261 unique patients with non-MS/atypical CNS inflammatory conditions attended the clinic and were assessed for NMOSD. All patients were tested for AQP4-IgG. 132 cases satisfied the 2015 NMOSD diagnostic criteria. Of these, 96 (73%) were AQP4-IgG positive and 36 (27%) AQP4-IgG negative. These 36 patients, were tested for MOG-IgG and 15/36 (42%) tested positive. This would account for 11% (15/132) of the total cohort of NMOSD patients (Fig. [1](#Fig1){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}). All MOG-IgG-negative patients were Caucasians with a median age of onset of 18 years (8--44 years) and median disease duration of 4.7 years (2--16 years). The predominant clinical phenotype of the demyelinating event was ON (60%), TM (21%), brain (12%), and brainstem (4%).Fig. 1Classification of non-MS/atypical demyelination based on 2015 NMOSD criteria, AQP4-IgG, and MOG-IgG testing. *NMOSD* neuromyelitis optica spectrum disorder, *AQP4 IgG* Antibody to aquaporin 4, *MOG-IgG* antibody to myelin oligodendrocyte glycoprotein, *OSD* optico-spinal demyelination with normal brain MRI Table 1Demographic, clinical, and radiological characteristics of the 15 NMOSD patients with MOG-IgGPatient no.AgeSexAge at onsetDisease duration (years)CourseTotal no. of eventsClinical phenotype (no. of attacks)First inter-attack intervalSpinal MRIBaseline brain MRICSF oligoclonal bandsEDSSCurrent treatment131F1813.4R13ON (13)\
TM (1)3 yearsLETMNormalNegative4Subcutaneous IGs (immunoglobulins) and oral prednisolone255M4411R7ON (2)\
TM (1) brainstem (1) brain syndrome (5)7 yearsShort mid thoracic lesionBrain stem, cortical and subcortical extensive demyPositive3.5Steroid & mycophenolate331F1516.4R2ON (1)\
TM (1)4 yearsLETMNormalNegative9Azathioprine and oral prednisolone421M182.5R5Brain stem (1)\
Brain syndrome (1)\
TM (1)\
ON (5)2 monthsMultiple short lesions on thoracic cordLarge area of high T2 signal in the posterior brainstem both sides of mid brainNegative1.5Azathioprine switched to rituximab522M174.7R\>7ON (\>7) and TM (2)2 monthsLETMNormalUnknown3Tocilizumab, IVIG six weekly and oral prednisolone630F282R2ON (1)\
TM (1)1 yearLETMCerebral ring enhancing lesion supracallosal subcorticalNegative0Mycophenolate723F814.4R3ON (2) TM (2) Brain syndrome (1)3 yearsLETMMultiple non-specific white matter lesionsNegative6Azathioprine and oral prednisolone824F176.9R2ON (1)\
TM (1)\
Brain syndrome (1)3 monthsLETMBrainstem, left cerebral peduncle, and few non-specific white matter lesionsNegative1Azathioprine and oral prednisolone914F104R3Brain syndrome (1) ON (3)\
TM (1)3 monthLETMBilateral hemispheric white matter changesNegative2.5Rituximab and mycophenolate1028M198.2R4ON (3)\
TM (1)6 yearsLETMNormalUnknown4Mycophenolate1144M1331R5ON (3)\
TM (2)17 yearsLETMNormalNegative3.5Azathioprine1239F363.1R2Brain stem (1)\
ON (2)2.2 yearsNormalLesion on ponsNegative (161)3Mycophenolate and oral prednisolone1342M383.6R2TM (1)\
Brain stem (1)2 monthsLETMPeri ependymal pons lesionUnknown6Azathioprine and oral prednisolone1428M262Single event1ON + LETMSimultaneouslyLETMNormalPositive1.5Mycophenolate1545M405Single event1ON + LETMSimultaneouslyLETMNormalNegative2None*F* female, *M* male, *R* relapsing, *ON* optic neuritis, *TM* transverse myelitis, *LETM* longitudinally extensive transverse myelitis, and *IVIG* intravenous immunoglobulins

While we tested all AQP4-IgG-negative patients for MOG-IgG (*n* = 36), only a proportion (33%) of AQP4-IgG-positive patients (*n* = 32) were tested (as double positives are exceptionally rare) (Fig. [1](#Fig1){ref-type="fig"}). None were definitely positive. However, one patient was 'low positive/possibly negative. This patient with one episode of long myelitis also had antinuclear antibodies (1/80 titre with homogenous pattern (nuclear antigens all negative) and was 'low positive' for anti-glycine antibodies too. The significance of the MOG-IgG in the context of these additional antibodies is uncertain and may reflect a heightened humoral autoimmune response rather than truly pathogenic dual positivity. This patient has not been included in the MOG cohort in this paper.

We also tested the majority of patients with a demyelinating syndrome referred to the service who did not fulfill the NMOSD criteria (125/129, 97%). Twenty-five (20%) were positive for MOG-IgG. Details of these cases will be the subject of an upcoming separate research paper and are not discussed further here.

We also assessed how many of the MOG-IgG patients with NMOSD phenotype had a relapsing course. Thirteen patients (86%) had a relapsing course. However, a relapsing course was the reason for referral to the clinic in the first place (*n* = 13/13). The median duration of illness for the relapsing patients was 4.7 years (2--16 years). The median inter-attack interval was 1 year (0.16--17) and median EDSS in the relapsing MOG group at last follow-up was 3 (0--9, Table [1](#Tab1){ref-type="table"}). All relapsing patient are on immunosuppressants (Table [1](#Tab1){ref-type="table"}).

We also assessed the proportion of patients with optic neuritis and long myelitis who fulfill Wingerchuk 2006 criteria \[[@CR6]\] that are MOG-IgG positive, as this is a clinical question often posed. Of the whole cohort of 261 patients, 75 patients had long myelitis and optic neuritis. Of these 49 were AQP4-IgG positive (66%) and 10 were MOG-IgG positive (13%, or 38% of AQP4-IgG-negative patients) and 16 remained seronegative (21%). Serial testing where done in 14/15 patients (13 relapsing); MOG-IgG was detected in all. Treatment with steroid or immunosuppression does not seem to have an effect on MOG-IgG serostatus in this cohort of predominantly relapsing patients (Table [2](#Tab2){ref-type="table"}).Table 2MOG-IgG testing in relation to disease course and immunosuppressive treatment. NA: not availablePatient no.Date of onsetDate of first relapseLast relapseDate of start on steroidDate of start on maintenance immunosuppressive treatmentFirst-positive MOG-IgG testSubsequent MOG test yearTitreComments1Jan 02May 05Jul 05Jan 08200920112013, 2014 both positiveNAData not clear if was on steroid in first or last relapse, but was on immunosuppressant when tested positive for MOG-IgG22004201120152014201420142015, 2016, 2017 all positive300Patient was not on steroid in first or last relapses, but was on immunosuppressant when tested positive for MOG-IgG after diagnosis and remained positive3Jan 99Apr 03May 03Unknown2003Apr 14Jul 14 positiveNAData not clear if was on steroid in first or last relapse, but was on immunosuppressant when tested positive for MOG-IgG subsequently4Sep 14Nov 14May 17Nov 14Dec 1420142015 positive300Patient was not on steroid in first relapse, but was on steroid and immunosuppressant in last relapse and when MOG-IgG tested and remained positive2016 positive4005Sep 10Oct 10Jul 13At onset201120122014, 2015, 2016 all positiveNAPatient was on reducing dose of steroid in first relapse, and on immunosuppressant and steroid in last relapse and when MOG-IgG was tested and remained positive6Aug 13Sep 14Sep 14Sep 14May 15Sep 142016, 2017 both positiveNAPatient was not on steroid in first relapse, was on steroid when tested for MOG-IgG initially and in 2016 but off steroid in 2017 and remained positive7200120042010At onset201020132014, 2016 both positiveNAPatient was not on steroid in first or last relapse, she was on immunosuppressant when tested for MOG-IgG subsequently.8Jul 08Nov 08Nov 08At onsetNov 08Apr 11May 11 positiveNAData unavailable if patient was on steroid in first relapse, she was on immunosuppressant when tested positive for MOG-IgG9Apr 12Jul 12Aug 15At onset201220122015, 2016 positiveNAPatient was on steroid in first relapse and when tested positive for MOG-IgG. She was also positive when was on steroid and immunosuppressant in subsequent relapses.10Mar 07Jul 13Dec 15At onsetJul-14Apr 142016 positiveNAPatient was not on steroid in first relapse, or first MOG-IgG test. He was on immunosuppressant in last relapse and when remained positive in subsequent testing1119842001Mar 13At onset20132015No further testsNANo available data whether patient was on steroid in first or last relapse, but he was on immunosuppressant when tested positive for MOG-IgG.12May 12Aug 14Aug 14At onsetMay 15May 152016 positiveNAPatient was not on steroid in first relapse, but was on steroid when tested positive for MOG-IgG and was on immunosuppressant on subsequent positive test13Oct 12Jan 13Jan 13At onsetAug 13Jul 132014 negative\
2015 positiveNAPatient was on steroid in first relapse, however, immunosuppressant was initiated after MOG-IgG returned positive in 2013, later test one year apart was negative in 2014, and subsequent test in 2015 was positive while still on immunosuppressant14Mar 14At onsetApr 14Apr 142015, 2016, 2017 all positiveNAOnly one event but patient chose to go on treatment15Jun 12At onsetNot on immunosuppressantJun 122015 positiveNANot on immunosuppression

Discussion {#Sec4}
==========

In a cohort of well-characterised NMOSD patients (*n* = 132), 73% were AQP4-IgG and 11% were MOG-IgG seropositive and 16% remained seronegative. MOG-IgG disease accounts for 42% of the AQP4 IgG-negative seronegative cohort. MOG-IgG was present in 38% of patients with long myelitis and optic neuritis who do not have AQP4 IgG.

86% (13/15) of our patients who satisfy criteria for NMOSD who are MOG-IgG-positive patients have relapsing disease, similar to a recent study \[[@CR7]\] who reported that 80% of their MOG-IgG-positive cohort (*n* = 50) followed a relapsing course. However, a relapsing course was the reason for referral to the clinic in the first place (*n* = 13/13) making this a biased sample. Long-term follow-ups of a cohort of MOG-IgG-positive patients after the very first event is required to obtain the true risk of relapse.

Importantly, 20% of patients with non-MS/atypical demyelination who do not satisfy criteria for NMOSD tested positive for MOG-IgG (Fig. [1](#Fig1){ref-type="fig"}). Double positive cases (both AQP4-IgG and MOG-IgG) are rare \[[@CR8]--[@CR10]\] with none of the tested patients were definite positives. Since we have tested only 52% (68/132) of the total NMOSD cohort for MOG-IgG, this requires further clarification in future studies.

In conclusion, our study provides the best possible answers at the current time on several questions on the frequency of MOG-IgG patients: NMOSD who are AQP4-IgG negative and MOG-IgG positive (42%), NMO (as per Wingerchuk 2006) with optic neuritis and long myelitis who are AQP4-IgG negative but MOG-IgG (13%). We also found that MOG-IgG is found in 20% of non-NMOSD/non-MS demyelination. It is also estimated that at least 11% of all NMOSD (as per 2015 criteria) is MOG-IgG positive.

Our study has important practical implications. First, the definite diagnosis of MOG-IgG-associated disease offers patients and physicians a better diagnostic label than seronegative NMOSD. Second, as nearly one in every two of seronegative NMOSD, and 1/5 of atypical non-MS demyelination is MOG-Ig positive, testing for these cohorts will be of high yield and worthwhile, compared to testing every demyelination (which in most Caucasian predominant populations is likely to be MS) with attendant costs and risk of false-positive results. Third, it is likely that the long-term disease course and therefore treatment strategies of AQP4-IgG and MOG-IgG is different. If this is the case, MOG-IgG status, should be part of inclusion/exclusion criteria or a variable for stratification in clinical trials. The latter issue may have importance for currently recruiting trials that include seronegative NMOSD.
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